Chemoimmunotherapy for multiple myeloma
- 15 April 1981
- Vol. 47 (8) , 1923-1929
- https://doi.org/10.1002/1097-0142(19810415)47:8<1923::aid-cncr2820470802>3.0.co;2-z
Abstract
The effect of chemoimmunotherapy consolidation treatment using alternating courses of alkylating agents and BCG was studied in 105 responding patients with multiple myeloma. The survival time of these patients was similar to that of responding patients treated on previous maintenance programs, indicating no apparent value from BCG for myeloma. The duration of unmaintained remission was longest in those with low numbers of residual plasma cells, and relapse usually developed within one year in patients with persistent serum myeloma peaks. Disease recontrol was achieved in 50% of relapsing patients whose median survival from retreatment was 20 months. Patient follow-up without chemotherapy until relapse was justified mainly for those responding patients with disappearance of myeloma proteins.This publication has 14 references indexed in Scilit:
- Successful Maintenance Immunotherapy by BCG of Non-Hodgkin's Malignant Lymphomas: Results of a Controlled TrialBritish Journal of Haematology, 1979
- Unmaintained remissions in multiple myelomaBlood, 1978
- Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancerCancer, 1978
- Combination therapy for multiple myelomaCancer, 1977
- Tumor growth patterns in multiple myelomaCancer, 1977
- Prognostic factors in multiple myelomaCancer, 1975
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975
- Serial Studies of Immunocompetence of Patients Undergoing Chemotherapy for Acute LeukemiaJournal of Clinical Investigation, 1974
- ACTIVE IMMUNOTHERAPY WITH B.C.G. FOR RECURRENT MALIGNANT MELANOMAThe Lancet, 1973
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958